Moleculin Announces Acceptance of Annamycin Data for Presentation at the 2026 American Society of Hematology (ASH) Annual Meeting
Globe Newswire•04/11/2026•11:00 ET
0
Key Highlights
- ➤Annamycin remission rates reached 43% and 36% versus 12% for placebo
- ➤MB-108 interim analysis covered the first 45 randomized relapsed/refractory AML patients
- ➤Independent Data Monitoring Committee recommended continuing all three treatment arms unchanged
- ➤Second interim analysis expected in early 2027
- ➤ASH accepted Annamycin Phase 2/3 data for December 12-15 presentation
Expert Statements
Walter Klemp, Chairman and Chief Executive Officer of Moleculin
“We are encouraged by these initial findings from our pivotal Phase 2/3 trial, particularly the remission rates observed in the Annamycin treatment arms. The independent Data Monitoring Committee's recommendation to continue the study without modification represents an important milestone for the program. We look forward to sharing these findings with the broader hematology community at ASH as we continue advancing Annamycin's development for patients facing this challenging disease”
First interim results from pivotal Phase 2/3 trial highlight encouraging remission rates in patients with relapsed or refractory AML
HOUSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced that an abstract highlighting data from its lead drug candidate, Annamycin, has been accepted for presentation at the 2026 American Society of Hematology (ASH) Annual Meeting, taking place December 12-15, 2026 in New Orleans, Louisiana.
Get started
Create a free account to read the full story.